Pharmaceutical ProductCached Profile
AXONICS
Active Ingredients (Generic):Unmapped
Therapeutic Area: Urology
LIFETIME PROMOTIONAL SPEND
$123,235
General Payments Aggregated (2021–2024)
Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
Post-Market Clinical Follow-up Study of the Rechargeable Axonics SNM System INS Model 5101 (R20) for the Indication of Fecal Incontinence (FI)
NOT_YET_RECRUITINGPhase N/ANCT07499258
Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Axonics External Trial System (ETS-02)
RECRUITINGPhase NANCT07335484
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt (ARTISAN-SNM)
COMPLETEDPhase NANCT03327948
Prospective, Non-randomized, Multicenter Clinical Evaluation of the Recharge Free Axonics SNM System (Model 4101)
ACTIVE_NOT_RECRUITINGPhase NANCT06186765
Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB)
COMPLETEDPhase NANCT02620410
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. MARC HODROFFMedical Doctor$13,208
Dr. AMANDEEP MAHALMedical Doctor$7,436
Dr. CAROLYN LANGFORDDoctor of Osteopathy$6,840
Dr. ZISHAN HIRANIMedical Doctor$2,270
Dr. SHARON STEELEMedical Doctor$2,231
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2024
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for AXONICS...